The U.S. Supreme Court turned down Novartis’ appeal to market a generic version of Amgen’s rheumatoid arthritis drug Enbrel. Enbrel is Amgen’s top-selling drug. (Reuters)
The Biden administration announced plans to send 20 million COVID-19 vaccine doses abroad. The U.S. has received more than four dozen requests for doses, with soaring case counts in countries like Nepal and India. (Politico)
Sanofi and GSK reported promising results for their COVID-19 vaccine in a Phase II clinical trial. The companies say a Phase III trial will begin in the coming weeks. (STAT)
The World Health Organization warned that the global pandemic isn’t over yet, even as some countries have achieved high vaccination rates. “It will not be over until it’s over everywhere,” said WHO Director-General Tedros Adhanom Ghebreyesus. (CNBC Weekly)
Soteria Biotherapeutics brought in a $42 million Series A investment backed by Roche to study its bispecific T cell engagers, or BiTEs. The biotech plans to examine an “on/off switch” that may address BiTE toxicity. (Endpoints News)
